Zelgen(SH:688266) Ge Long Hui A P P·2026-01-30 09:44Core Viewpoint - Zai Jian Pharmaceutical (688266.SH) expects significant revenue growth in 2025, with projected revenues between 796.49 million and 828.99 million yuan, representing a year-on-year increase of 49.45% to 55.55% [1] Financial Performance - The company anticipates a net loss attributable to shareholders of the parent company ranging from 191.39 million to 139.60 million yuan for 2025, an increase in losses by 1.76 million to 53.56 million yuan compared to the previous year [1] - The expected net loss after deducting non-recurring gains and losses is projected to be between 237.87 million and 172.53 million yuan, reflecting an increase in losses by 1.37 million to 66.71 million yuan year-on-year [1] Revenue Drivers - The significant revenue growth is primarily attributed to an increase in drug sales, particularly due to the inclusion of recombinant human thrombin in the national medical insurance drug list, which has led to a noticeable increase in sales [1] - The approval and commercialization of Jikaxitini tablets during the reporting period have also contributed to the revenue growth [1] Expense Overview - Despite the revenue increase, the company continues to report negative net profits, with the anticipated losses attributed mainly to rising sales and research and development expenses [1]